SecBot SecBot
8-K ·Filed May 21, 2026

ZNTL

Zentalis Pharmaceuticals, Inc.
BULLISH
Impact 6/10
Horizondays Processed5mo ago SEC0001725160-26-000045
8-K context-dependent: Items 7.01, 8.01
Actionable Insight ▲ Bullish

The Phase 1b MUIR data shows azenosertib + paclitaxel meaningfully improves ORR and PFS vs. historical paclitaxel monotherapy benchmarks in heavily pre-treated PROC. The 250 mg intermittent dose suggests manageable safety. With the company's core registration strategy in Cyclin E1-positive monotherapy, this combination proof-of-concept expands the total addressable market. Expect stock volatility around the ASCO presentation on June 1, but given the early-phase nature and small sample sizes, the filing alone is a moderate positive catalyst, not a transformational event.

DirectionBullish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.06
T+0 close · May 21, 2026 · via day close
Latest settled
−9.36%
T+60 · $3.68
Vs SPY
−12.55%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 22 $4.06entry
  2. T+1 · 6mo ago −2.46%α −3.05% · $3.96
  3. T+5 · 6mo ago −1.97%α −3.63% · $3.98
  4. T+20 · 5mo ago −8.87%α −7.45% · $3.70
  5. T+60 · 3mo ago −9.36%α −12.55% · $3.68

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Zentalis Pharmaceuticals announced Phase 1b MUIR trial data for azenosertib plus paclitaxel in platinum-resistant ovarian cancer (PROC), showing a 39.1% ORR and 7.3-month median PFS across all cohorts (n=46), with a 50% ORR and 9.2-month median DOR at the 250 mg intermittent dose (n=12). The data will be presented at ASCO 2026. As a pre-revenue biotech with a $264M market cap, the filing is noteworthy for pipeline progress but does not change the risk profile.

Key Facts

  • ORR of 39.1% across all four dose cohorts (n=46) in PROC patients, vs. historical paclitaxel monotherapy ORR of ~30%.
  • At the 250 mg intermittent dose (n=12), ORR was 50.0% including one complete response, with a median DOR of 9.2 months.
  • Median PFS of 7.3 months across all cohorts vs. historical paclitaxel monotherapy median PFS of ~4 months.
  • One Grade 5 event (sepsis) previously reported in June 2024, assessed as related to azenosertib by investigator.
  • Data will be presented at ASCO 2026 (June 1, 2026).

Financial Impact

No financial data in filing; clinical data supports potential expansion of azenosertib label into combination settings, which could increase peak revenue opportunity if approved.

clinical trial datapipeline value

Risk Factors

  • Small Phase 1b sample (n=46), data may not replicate in larger randomized trials.
  • Grade 5 event (sepsis) attributed to azenosertib remains a safety concern.
  • No financial data filed, company has significant cash burn with no approved products.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
60% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001725160-26-000045
Document: asco2026datapressreleasefi.htm0001725160-26-000045
Document: 0001725160-26-000045-index-headers.html0001725160-26-000045
Document: 0001725160-26-000045-index.html0001725160-26-000045
Document: 0001725160-26-000045.txt0001725160-26-000045

Track record

18 reports on ZNTL

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +51.42% at T+60 after the Aug 14, 2026 report. 6 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $1.62 Now $1.60 −1.23% settles Feb 12
  2. Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.80 Now $1.60 +11.11% settles Feb 8
  3. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $2.06 Now $1.60 −22.33% settles Jan 26
  4. Oct 18, 202629d ago Press Release Bullish 7/10 Entry $2.30 Now $1.60 −30.43% settles Jan 14
  5. Oct 1, 20266w ago Press Release Neutral 2/10 Entry $2.52 Now $1.60 −36.51% settles Dec 29
  6. Aug 14, 202613w ago 8-K Bearish 6/10 Entry $3.71 to $1.80 Now $1.60 +56.82% ▲ +51.42% +48.47% vs SPY
  7. Aug 13, 202613w ago Press Release Bearish 6/10 Entry $3.56 to $1.74 Now $1.60 +55.06% ▲ +51.12% +48.08% vs SPY
  8. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.75 to $4.03 Now $1.60 −57.33% ▲ +7.47% +4.20% vs SPY
  9. Jun 1, 202624w ago Press Release Neutral 2/10 Entry $3.95 to $3.89 Now $1.60 −59.49% ▼ −1.52% −2.64% vs SPY
  10. May 21, 202625w ago Press Release Bullish 6/10 Entry $4.06 to $3.68 Now $1.60 −60.59% ▼ −9.36% −12.55% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 7h 32m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 21, 2026